BIIB

#489
Biogen Inc. Common Stock
180.68 USD
+2.44%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
177.45
180.85
Intervallo Annuale
114.66
202.41
Variazione giornaliera
+2.44%
Variazione Mensile
-1.14%
Variazione di 6 mesi
+24.83%
Variazione Annuale
+51.88%
Chiusura Precedente
176.37
Apertura
177.71
Bid
Ask
Minimo
177.45
High
180.85
Volume
150
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 26.52 B
  • Employee 7 500
  • Founded 1978
  • CEO Chris Viehbacher
  • Website www.biogen.com
  • Headquarter Delaware, United States
  • FIGI BBG000C17X76
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
20.02
Rapporto prezzo/fatturato
2.62

Biogen Inc

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

Notizie